Zydus announces settlement with Aptalis on CANASA

Cadila Healthcare Logo

Cadila Healthcare, a global pharmaceuticals company and its subsidiary Zydus Pharmaceuticals Inc. (USA), announced on Monday that the company has settled a patent litigation relating to the Aptalis’s CANASA.

Cadila Healthcare, a global pharmaceuticals company and its subsidiary Zydus Pharmaceuticals Inc. (USA), announced on Monday that the company has settled a patent litigation relating to the Aptalis’s CANASA.

As a result of the settlement, its US subsidiary, Zydus Pharmaceuticals will be able to market its generic version of CANASA in the United States beginning on June 13, 2019 or earlier under certain circumstances.

Zydus  Cadila previously received tentative approval from the USFDA to market its generic version of CANASA. CANASA is indicated to treat mildly to moderately active ulcerative colitis. Zydus Cadila’s generic product will be produced at the group’s tropical plant at Ahmedabad.

Meanwhile, the stock was trading lower by 0.10% at Rs 482 per share on BSE at 1346 hours.
Full Article Here

 

Submit a Comment

Your email address will not be published.

Subscribe to get the latest news